PatientsVisitorsLocations & ServicesAbout the RegionJoin Our TeamPhysicians
Find:  Locations | Services
Pathology and Laboratory Medicine HomeTest and Services CatalogueTransfusion Medicine Product CataloguePolicy and ProcedureJob AidsSpecimen Collection and TransportRequisitionsAntibiogramsCytogenetics and Related Medical Genetics EssentialsMicrobiology EssentialsTransfusion EssentialsReference RangesLaboratory SuppliesAcute Care SCM GuidelinesContact InformationPhysician Access to Patient Results
Pathology and Laboratory Medicine
Product Catalogue

​Fibrinogen Concentrate

Transfusion Medicine

​Alternate Product Names
  • ​RiaSTAP™
  • ​Treatment of acute bleeding in congenital fibrinogen deficiency
  • Treatment of acute bleeding in acquired fibrinogen deficiency (off-label)
​Resource Information
​Product Monographs:

More Information:

Product Size
​1 gm
Pretransfusion Testing Requirements
  • ​None required
Forms Required


  • Consultation with Transfusion Medical Director required
  • Indicate volume required
  • ​Pasteurized, preservative-free, lyophilised human fibrinogen concentrate
  • Manufacturing effectively protects against enveloped viruses, including HIV, HBV and HCV, and the non-enveloped virus HAV
  • Contains 0.9-1.3 grams of fibrinogen per vial
  • Stored at room temperature
  • Half-life ~77 hours (in vivo)
  • Approximate product equivalency for replacement of 1 gram of fibrinogen:
​Fibrinogen concentrate (RiaSTAP™)​1 vial (1 gram)
​50.0 mL (reconstituted)
​Cryoprecipitate​3 units
​30.0 mL
​Plasma (FP or FFP)​1 unit
​350.0 mL
  • Consideration for use as an adjunct to treatment of profound acquired hypofrinogenemia with clinically significant hemorrhage, including:
    • Disseminated Intravascular coagulation (DIC)
    • Obstetrical hemorrhage
  • There is no evidence of fibrinogen concentrate (RiaSTAP™) superiority over plasma or cryoprecipitate administration for fibrinogen replacement
  • Choice of product for fibrinogen replacement and target fibrinogen level is a clinical decision based on patient condition
  • Pediatric patients – RiaSTAP™ may exhibit a shorter half-life due to increased clearance
  • ​See product monograph
  • Contains human protein; informed patient consent required for this product
  • Maximum intravenous infusion rate of 5 mL per minute (100 mg/minute; 1 reconstituted vial over 10 minutes)
  • Administer within 8 hours of reconstitution

​If you choose to print this information, it is valid only on date of print.

Laboratory Controlled Document LSM-844 v2

Last Modified: Thursday, February 7, 2019 |
Questions or feedback about this page?